EZH2: A Critical Competing Endogenous RNA in Cancer Research - A Scoping Review
===============================================================================

* Sadra Salehi-Mazandarani
* Sharareh Mahmoudian-Hamedani
* Ziba Farajzadegan
* Parvaneh Nikpour

## Abstract

In recent years, research on the competing endogenous RNAs (ceRNAs) in cancer is in full swing. These investigations are discovering the importance of critical RNAs in cancer progression. Enhancer of zeste 2 polycomb repressive complex 2 subunit (*EZH2*) is one of these RNAs that has been identified as a potential therapeutic target in many types of cancer. Up to now, many studies have been conducted to elucidate ceRNA role of *EZH2* in cancer. Due to EZH2’s dual role as an oncogene and tumor suppressor in cancer, a more thorough exploration of its ceRNA functions may enhance clinical approaches to cancer treatment. In the current scoping review, we searched online databases including PubMed, Web of Science, Scopus, Embase, Cochrane Library, and Google Scholar to identify experimentally-validated ceRNA axes including *EZH2* in human cancers. We identified 62 unique axes consisting of 30 microRNAs (miRNAs), 31 long non-coding RNAs (lncRNAs), 9 messenger RNAs (mRNAs), and 14 circular RNAs (circRNAs). Notably, *SPRY4-IT1* - miR-101-3p - *EZH2* and *XIST* - miR-101-3p - *EZH2* were recurrent axes observed in multiple cancer types. Among the most frequent miRNAs were miR-101-3p, miR-144-3p, and miR-124-3p, and ceRNAs including *SPRY4-IT1*, *XIST*, *SNHG6*, *HOXA11-AS*, *MALAT1*, and *TUG1* emerged as frequent competitors of *EZH2* for miRNA binding. This scoping review highlights the prevalence and diversity of *EZH2*-containing ceRNA axes in cancer, suggesting their potential as therapeutic targets. Future research should delve deeper into these axes to elucidate their functional significance and assess their clinical applicability.

Keywords
*   Enhancer of zeste 2 polycomb repressive complex 2 subunit
*   RNA
*   Competitive Endogenous
*   Neoplasms
*   RNA
*   Untranslated

## 1. Introduction

EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) is the catalytic subunit of the polycomb repressive complex 2 (PRC2), which suppresses gene expression by methylation of lysine 27 of histone 3 (H3K27). This epigenetic modification is thought to silence more than 200 tumor suppressor genes (1). In addition, EZH2 can also methylate non-histone proteins and affect their transcriptional activity. For instance, EZH2 methylates GATA4 transcription factor and reduces its acetylation by p300, resulting in the inhibition of GATA4-mediated transcription (2). Moreover, EZH2 can also activate downstream genes in a PRC2-independent way by methylation of non-histone proteins (3). Through these mechanisms, EZH2 is involved in various cellular processes, such as cell cycle regulation, autophagy, apoptosis, DNA repair and cellular senescence. EZH2 is also associated with many diseases, especially cancer (4).

*EZH2* is overexpressed in many cancers, such as breast, prostate, endometrial and bladder cancers, melanoma, and other malignancies, where it disturbs various cellular processes such as proliferation, apoptosis, migration, and invasion (5). Moreover, EZH2 is subjected to post-translational modifications that modulate its function and activity in cancer. For example, phosphorylation of EZH2 can either promote (pT350-EZH2) or inhibit (pT487-EZH2) cell invasion and metastasis. O-GlcNAcylation, acetylation, and methylation of EZH2 affect proliferation, apoptosis, migration, and metabolism of cancer cells. Ubiquitination of EZH2 can target it for degradation, while deubiquitinases like ZRANB1 stabilize EZH2 and enhance its oncogenic effects (6). However, EZH2 can also act as a tumor suppressor in some cancers, where its loss or inactivation facilitates cancer progression. For instance, T-cell acute lymphoblastic leukemia (T-ALL) is to a large part driven by oncogenic activation of NOTCH1 signaling, which reduces the activity of PRC2 and the histone H3K27me3 repressive mark in T-ALL cells. Inactivation of EZH2 by phosphorylation at its Ser 21 subsequently induces anti-apoptotic genes, such as *IGF1*, *BCL2*, and *HIF1A*, and increases cell adhesion-mediated drug resistance in multiple myeloma cells (7).

*EZH2* expression is also regulated by many microRNAs (miRNAs), which are often deregulated in cancer. Examples of such miRNAs are miR-98 in nasopharyngeal carcinoma (8), miR-101-3p in esophageal squamous-cell carcinoma (ESCC) (9) and miR-124 in gastric cancer (GC) (10). The dysregulation of these miRNAs and their consequent effect on the *EZH2* expression contribute to the aggressive behaviors of these cancers. Therefore, the regulation and role of *EZH2* in cancer is a topic of significant interest to researchers in the field.

RNAs molecules in the cells communicate with each other through shared miRNA response elements (MREs), which act as the building blocks of a novel language and are called competing endogenous RNAs (ceRNAs) (11). Many studies suggest that *EZH2* participates in cancer progression via acting as a member of a ceRNA axis (12–15). As explained by these studies, the RNA of *EZH2*, as part of ceRNA axes, can engage in cancer progression, metastasis, cancer cell proliferation and epithelial-mesenchymal transition (EMT) (Figure 1).

![Figure 1.](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2024/04/22/2024.04.22.24306181/F1.medium.gif)

[Figure 1.](http://medrxiv.org/content/early/2024/04/22/2024.04.22.24306181/F1)

Figure 1. *EZH2*-related competing endogenous RNA (ceRNA) axes and their main outcomes in cancer.
*EZH2* competes with ceRNAs for binding to the same miRNAs based on their miRNA response elements (MREs) and forms ceRNA axes. These interactions have critical outcomes in cancer such as affecting on cellular proliferation, suppression, and metastasis.

The current scoping review provides a comprehensive overview of the literature on ceRNA axes including *EZH2* in cancer. While previous studies have exclusively explored the roles of these ceRNA axes in different cancers, this scoping review specifically maps the experimentally validated ceRNA axes containing *EZH2* in cancer and describes the gaps and opportunities regarding employing *EZH2* as a promising targeting component in cancer therapy.

## 2. Materials and methods

This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) (16).

### 2.1. Review Question

Which ceRNA axes containing *EZH2* have been identified in the field of cancer?

### 2.2. Selection criteria

Inclusion criteria included: 

1.  The *EZH2* RNA has been assessed in any type of cancer.

2.  The ceRNA axis has been assessed in human samples.

3.  *EZH2* has competition with at least one other ceRNA to sponge a miRNA.

4.  The correlations of *EZH2* and other ceRNA(s) with the miRNA(s) have been validated based on the experimental analyses (Not merely bioinformatic-based methods).

Exclusion criteria included: 

1.  Review studies

2.  Studies not in English

3.  Retracted studies

4.  Studies not specified to cancer

5.  Studies in which a specific state of cancer (for example evaluating effects of a drug) have been examined

6.  Congresses abstracts

### 2.3. Literature Search Strategy

Online literature search was performed till 6th November 2023 in the PubMed, Web of Science, Scopus, Embase, Cochrane Library, and Google Scholar (first 100 hits) utilizing a developed search query (Supplementary file 1). An attempt was made to contact authors in case of missing information via email.

### 2.4. Screening and data extraction

Records were imported to EndNote software ver. X7 and duplicated studies were removed. Two reviewers (SSM and SMH) independently screened title and abstracts of the studies to select relevant studies. Then, the full texts of the selected studies were assessed against inclusion and exclusion criteria. Consensus was achieved through discussion with another reviewer (PN) to resolve any disagreements.

An excel datasheet was prepared for extracting the data and two reviewers (SSM and SMH) independently performed data extraction from the included studies. Extracted information contained the name of the first author, year of publication, country of origin (the country of the corresponding author), type of cancer, ceRNA axis, method of interaction identification and validation, the main role of the axis, and references. A third reviewer (PN) was consulted in case of disagreement.

### 2.5. Visualization of the ceRNA axes

Cytoscape software (version 3.8.1) (17) was utilized to visualize ceRNA axes including *EZH2* which were identified through the previous steps.

## 3. Results

### 3.1. Characteristics of the included studies

2233 studies were initially identified through online search, among which, 1359 duplicates were omitted. By screening titles and abstracts, 787 studies were excluded, and 27 studies were removed via reading the full texts. Finally, 60 studies were recruited in the current study based on the mentioned criteria. The number of studies at each step of the study selection process is indicated in a PRISMA flowchart (Figure 2). The data extracted from the included studies has been shown in table 1. Excluded studies based on the full text examination with their reason of exclusion are shown in supplementary file 2.

![Figure 2.](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2024/04/22/2024.04.22.24306181/F2.medium.gif)

[Figure 2.](http://medrxiv.org/content/early/2024/04/22/2024.04.22.24306181/F2)

Figure 2. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of the search results and number of records at each stage,
ceRNA: competing endogenous RNA, EZH2: enhancer of zeste 2 polycomb repressive complex 2 subunit

View this table:
[Table 1.](http://medrxiv.org/content/early/2024/04/22/2024.04.22.24306181/T1)

Table 1. The main characteristics of included studies

All the included studies were from China and have been conducted between the years of 2014 to 2023. The identified studies have been performed in cancers consist of colorectal, gastric, oral squamous cell carcinoma (OSCC), lung, bladder, glioma, hepatocellular carcinoma (HCC), prostate, esophageal squamous cell carcinoma, pancreatic carcinoma, cholangiocarcinoma, rectal, ovarian, tongue squamous cell carcinoma, cutaneous squamous cell carcinoma, endometrial, papillary thyroid carcinoma, thyroid, laryngeal squamous cancerous, osteosarcoma, and breast. Totally 62 unique axes were identified. There were 30 miRNAs, 31 long non-coding RNAs (lncRNAs), 9 messenger RNAs (mRNAs), and 14 circular RNAs (circRNAs) in the axes. A ceRNA network including these axes has been shown in figure 3.

![Figure 3.](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2024/04/22/2024.04.22.24306181/F3.medium.gif)

[Figure 3.](http://medrxiv.org/content/early/2024/04/22/2024.04.22.24306181/F3)

Figure 3. *EZH2*-related ceRNA network in cancer.
Orange, blue, purple, and green colors represent mRNAs, circRNAs, lncRNAs, and miRNAs, respectively.

Both experimental and bioinformatic methods have been utilized in the included studies to identify and confirm the interactions among ceRNAs. Experimental methods were such as dual luciferase reporter assay, luciferase reporter, quantitative reverse transcriptase PCR (qRT-PCR), western blot, RNA immunoprecipitation (RIP) and RNA pull-down assays. For bioinformatic analyses, studies used online databases such as TargetScan (18) and CircInteractome (19). In all the included studies, a ceRNA axis including *EZH2*, as a critical ceRNA, as well as the role of this axis on the studied cancer were disclosed. Three of the included studies had examined the ceRNA axes in the context of exosomes (14, 20, 21).

### 3.2. Common *EZH2*-related axes, miRNAs and ceRNAs

*SPRY4-IT1* - miR-101-3p – *EZH2* axis is reported in glioma (22), bladder cancer (23) and cholangiocarcinoma (24). *XIST* – miR-101-3p – *EZH2* was another axis reported in two cancer types including GC (25) and ESCC (26). Eleven miRNAs including miR-101-3p (9, 22–32), miR-144-3p (12, 33–38), miR-124-3p (10, 20, 39–41), miR-138-5p (42–45), miR-214-3p (46–49), miR-26a-5p (47, 50–52), miR-1297 (53, 54), miR-137-3p (55, 56), miR-217-5p (57, 58), miR-382-5p (59, 60), and miR-600 (61, 62) appeared in more than one cancer type/study. Of note, one study (63) did not specify whether they examined the miR-101-3p or other variants of the miR-101 under investigation, so we did not consider it as a common miRNA.

*SPRY4-IT1* (22–24), *XIST* (25, 26, 41, 56), *SNHG6* (9, 47, 50), *HOXA11-AS* (48, 53), *MALAT1* (29, 64), and *TUG1* (37, 60) were ceRNAs repeated in several *EZH2*-related ceRNA axes.

## 4. Discussion

### 4.1. Importance of *EZH2* in cancer

EZH2 is an important regulator in the field of cancer. Many studies have unveiled the roles of EZH2 in different types of cancer. Here we discuss the identified aspects of EZH2 in some selected cancer types.

EZH2 RNA and protein is upregulated in cancerous compared to the non-cancerous colorectal tissues (65). In a meta-analysis in 2017, it was reported that increased expression of EZH2 is associated with better overall survival in patients with colorectal cancer (66). Another study suggested that the inhibition of p21cip1 (also known as P21) expression by EZH2 could result in the activation of the Wnt/β-catenin signaling pathway, which is responsible for regulating the stem-like properties of colorectal cancer cells (67).

EZH2 is overexpressed in cancerous compared to non-cancerous gastric tissues and it correlates with poor prognosis. By regulation of P21 expression, EZH2 affects the proliferation of GC cells (68). Moreover, single nucleotide polymorphisms (SNPs) in *EZH2* correlate with the risk of GC (69, 70). For example, rs734004 genotype CG, rs734005 genotype TC, and rs2072407 genotype TC, all are associated with decreased susceptibility to GC (70). EZH2 promotes cell invasion and progression of GC through activating EMT events and inhibiting cellular senescence (71, 72). Therefore, targeting EZH2 can be a therapeutic method for treating GC (73).

EZH2 is overexpressed in OSCC. Inhibition of EZH2 leads to increase of apoptosis as well as reduction of proliferation, migration and metastasis in this type of cancer (74). Overexpression of EZH2 is associated with shorter survival in patients with OSCC (75). There is also an association between OSCC initiation and the level of EZH2 expression. It has been indicated that high expression of EZH2 in the epithelium of oral leukoplakia, which is the most common potentially malignant disorder of oral mucosa, is linked to a greater risk of developing OSCC (76, 77).

In non-small-cell lung cancer (NSCLC) patients, higher expression of EZH2 correlates with poorer prognosis (78). Expression of EZH2 is also associated with smoking and the expression of KRAS and BRAF in this type of cancer (78). Through suppressing transcription of mesenchymal genes, EZH2 induces mesenchymal to epithelial transition and then tumor colonization in NSCLC (79). The pharmacological values of EZH2 in NSCLC has been reviewed, recently (80).

### 4.2. *EZH2*-related ceRNA axes in cancer

*EZH2* has been identified as a critical ceRNA in various types of cancer. In the current scoping review, we systematically searched and collected the studies in which *EZH2* has been reported as a ceRNA, in a context of axis, by utilizing experimental approaches. Based on the table 1, in some types of cancer, role of *EZH2* as a ceRNA has not been well investigated. However, in some others such as colorectal, gastric and lung cancers, a considerable number of studies have delt with *EZH2* as a critical ceRNA. In these *EZH2*-related ceRNA axes, *EZH2* not only exerts a pivotal influence on the cancer progression, but the ceRNA(s) that compete with *EZH2*, along with the miRNAs present in these axes, play a fundamental role. In fact, the whole axis should be considered as a critical unit. Few of the included studies have been investigated ceRNA axes in exosomes (14, 20). Exosomal ceRNAs are critical for cellular communication in cancer. Their dysregulation affects proliferation, differentiation, and apoptosis of cancerous cells (81).

In the following sections, we discuss common ceRNA axes, miRNAs and ceRNAs among the included studies.

#### 4.2.1. Common ceRNA axes

Among the axes reported in the current study, there were two axes which were common among different cancers. These axes include *SPRY4-IT1* - miR-101-3p – *EZH2* and *XIST* – miR-101-3p – *EZH2*. In this section, we discuss these common axes.

*SPRY4-IT1* - miR-101-3p – *EZH2* ceRNA axis has been reported in glioma, bladder cancer, and cholangiocarcinoma (22–24). *SPRY4-IT1* has been identified as an oncogene in bladder cancer. Its expression correlates with apoptosis, proliferation and migration in this type of cancer (23). *SPRY4-IT1* is overexpressed in cholangiocarcinoma and its expression positively correlates with poor survival. Knockdown of *SPRY4-IT1* in cholangiocarcinoma, promotes apoptosis and decreases proliferation, invasion and migration (24). In these cancers, *SPRY4-IT1* regulates the expression of *EZH2* via sponging miR-101-3p (22–24).

*XIST* – miR-101-3p – *EZH2* ceRNA axis has been reported as a critical axis in GC and esophageal squamous cell carcinoma with *XIST* upregulation reported in both cancers (25, 26). In GC, high expression of *XIST* positively correlates with tumor size, tumor, node, metastasis (TNM) stage, invasion, and metastasis (25). In esophageal squamous cell carcinoma, *XIST* expression associates with invasion, proliferation, and migration of cancerous cells and patients with its higher expression, have shorter survival (26). In both cancers, *XIST* expression can be regulated by *EZH2* through sponging miR-101-3p (25, 26).

The recurrence of these two commonly observed ceRNA axes across various types of cancer emphasizes their crucial role in the development of cancer. These axes serve as intricate regulatory networks, orchestrating gene expression patterns that drive tumorigenesis and progression. The fact that they are found in different cancer types suggests a consistent mechanism of disruption in cancer cells, which presents promising opportunities for targeted interventions. Utilizing these ceRNA axes as diagnostic biomarkers or therapeutic targets has great potential for enhancing precision oncology strategies. Further investigation into their mechanistic underpinnings and clinical implications is warranted to harness their full therapeutic utility in combating cancer.

#### 4.2.2. Common miRNAs in the axes

Among the included studies, there were common miRNAs interacting with *EZH2* in various types of cancer or in one type based on different studies. Eleven miRNAs including miR-101-3p, miR-144-3p, miR-124-3p, miR-138-5p, miR-214-3p, miR-26a-5p, miR-1297, miR-137-3p, miR-217-5p, miR-382-5p, and miR-600 were the common miRNAs. Here we briefly discuss the implication of these miRNAs in different cancer types.

In twelve included studies, which were conducted on OSCC (29, 31), esophageal squamous cell carcinoma (9, 26, 30), GC (25, 27), HCC (28), bladder cancer (23), endometrial cancer (32), cholangiocarcinoma (24), and glioma (22), miR-101-3p has shown a correlation with *EZH2*. miR-101-3p has been reported as a critical miRNA in cancer. miR-101-3p acts as a tumor suppressor in NSCLC through targeting *MALAT-1* and PI3K/AKT signaling pathway (82). In GC, miR-101-3p exhibits tumor suppressor properties by inhibiting cell proliferation and induction of apoptosis via regulation of *PIM-1* expression (83). However, there are also some studies suggesting that miR-101 functions as an oncogene, particularly in vivo, and increased levels of miR-101-3p have been associated with poorer survival outcomes in ovarian cancer patients (84). Detailed cancer-related crucial roles of miR-101-3p has been reviewed elsewhere (85).

Seven of the included studies reported ceRNA axes including miR-144-3p. These studies were performed in cancers including colorectal (12, 35), lung (36), gastric (38), endometrial (34), OSCC (33), and osteosarcoma (37). miR-144-3p is dysregulated in cancers and can have both tumor suppressive and oncogenic roles depending on its target genes (86).

miR-124-3p has been reported in five of the included studies. These studies have been conducted in cancers including gastric (10), lung (20), prostate (39), ovarian (40), laryngeal squamous cell carcinoma (41). miR-124-3p has association with initiation, progression, and survival in cancer (87).

miR-138-5p and miR-214-3p have been reported, separately, in four studies. miR-138-5p have been reported in OSCC (42, 45), glioma (44) and cutaneous squamous cell carcinoma (43). miR-214-3p have been presented in HCC (46, 49), glioma (48), and colorectal cancers (47). miR-138-5p has been reported as a tumor suppressive miRNA preventing proliferation of cancerous cells. It performs this role by binding to the mRNAs producing oncogenic proteins (88). miR-214-3p is dysregulated in cancer and can both induce or prevent the proliferation of cancerous cells (89).

miR-26a-5p has been reported in four studies. The studies were performed in colorectal (47, 50, 51) and bladder cancers (52). The importance of this miRNA has been reported in different cancers. For instance, circulating levels of miR-26a-5p in plasma of patients with pediatric rhabdomyosarcoma are downregulated. Furthermore, patients with higher expression of miR-26a-5p have longer overall and progression free survival in this type of cancer (90). miR-26a-5p is also downregulated in breast cancer tissues. It can inhibit proliferation, sensitivity to chemotherapy, and metastasis of breast cancer cells (91).

miRNAs including miR-1297 (53, 54), miR-137-3p (55, 56), miR-217-5p (57, 58), miR-382-5p (59, 60), and miR-600 (61, 62) separately, were reported in two studies. The important association of these miRNAs with cancer progression have been uncovered (92–96). For example, miR-1297 expression is deregulated in cancer and affect tumorigenesis by playing oncogenic or tumor-suppressive roles (92). miR-217-5p is also dysregulated in many types of cancer and its expression is influenced by various upstream regulators including lncRNAs and circRNs (93).

#### 4.2.3. Common ceRNAs in the axes

Among the ceRNAs in the axes extracted from included studies, some were more frequent than others, including *SPRY4-IT1, XIST*, *SNHG6*, *HOXA11-AS*, *MALAT1*, and *TUG1* which we briefly discuss these RNAs in this section.

*SPRY4-IT1* has been reported in three of the included studies (22–24) and in all of them it competes with *EZH2* for binding to the miR-101-3p. lncRNA *SPRY4-IT1* is a critical RNA in cancer. For instance, it is overexpressed in prostate cancer and through the PI3K/AKT signaling pathway, promotes proliferation of cancerous cells (97). In breast cancer, upregulation of *SPRY4-IT1* induces NF-κB signaling pathway by which promotes cell proliferation and inhibits apoptosis (98).

*XIST* has been reported in four studies. It is reported to compete with *EZH2* for binding to miR-101-3p in GC (25) and ESCC (26) miR-137-3p in colorectal cancer (56), and miR-124-3p in laryngeal squamous cell carcinoma (41). The alteration of *XIST* expression in cancer has significant implications for cell growth, invasion, response to chemotherapy, and metastasis. The mechanisms by which it exerts these roles have been reviewed elsewhere (99, 100).

*SNHG6* has been reported in three of the included studies. These studies show that *SNHG6* competes with *EZH2* for binding to the miR-214-3p and miR-26a/b in colorectal cancer (47, 50) and miR-101-3p in esophageal squamous cell carcinoma (9). A meta-analysis, published in 2020, has reported the correlation of *SNHG6* expression with advanced TNM stage, tumor invasion depth, lymph node metastasis, and distance metastasis in human cancers (101).

*HOXA11-AS* has been reported as a *EZH2* competitor in GC (53) and glioma (48). *HOXA11-AS* participates in cancer development through various mechanisms such as epigenetic modifications in the nucleus and acting as a ceRNA in the cytoplasm (102) which have made it a promising therapeutic target in the field of cancer.

*MALAT1* is another lncRNA which is reported as a *EZH2* competitor in OSCC (29) and colorectal cancer (64). *MALAT1* is mostly overexpressed in human cancers and its expression is associated with tumor size and stage as well as patients’ poor survival (103). *MALAT1* has been recently identified as an important RNA which enhances cellular resistance to chemotherapy (104).

Two of the included studies have reported *TUG1* as a competitor of *EZH2* to bind to miR-144-3p and miR-382-5p in osteosarcoma (37) and pancreatic cancer (60), respectively. *TUG1* exhibits abnormal expression in human cancers and, by recruiting specific RNA-binding proteins, it induces the expression of target genes. Additionally, it functions as an important ceRNA, affecting the development of cancerous cells (105).

### 4.3. Strengths, limitations, and suggestions for the future studies

The current scoping review study possesses several strengths. First, different databases were systematically searched. Furthermore, we focused on experimentally validated ceRNA axes rather than those only predicted through prediction algorithms. Finally, we searched ceRNA axes in all types of cancers and provided a comprehensive view of *EZH2* as a ceRNA in cancer.

As for the limitation of the current scoping review, there are various constraints that need to be considered when interpreting the findings, including the absence of relevant articles in certain types of cancers like melanoma and kidney cancer, as well as the potential publication bias regarding studies with null or negative findings.

This scoping review presents recommendations for future research. An imperative exists for the thorough exploration of common ceRNA axes, miRNAs and ceRNAs, given their considerable significance in cancer biology. It is essential to delve deeper into their underlying mechanisms to fully exploit their therapeutic potential in the management of cancer. On the other hand, while *EZH2* has been identified as a crucial ceRNA in certain cancers, its role remains insufficiently studied in others, thus necessitating further investigation to gain insights into the molecular characteristics of EZH2 in other cancer types. Furthermore, exploring these axes in exosomes could provide valuable indications of their relevance as a prominent subject in cancer research.

## 5. Conclusions

Multiple lines of evidence have reported vital functions of *EZH2* in cancers. In this scoping review, we summarized the emerging insights on ceRNA axes including *EZH2* in cancer which have been experimentally validated. These axes contain competition of *EZH2* with other critical ceRNAs for binding to the miRNAs, thereby influencing cancer progression. The current study provides a comprehensive perspective of these ceRNA axes in cancer focusing on *EZH2*. Further studies are needed to further investigate these axes and assess their clinical utilities.

## Supporting information

Suppl. File 1 [[supplements/306181_file02.docx]](pending:yes)

Suppl. File 2 [[supplements/306181_file03.docx]](pending:yes)

## Data Availability

All data produced in the present study are available upon reasonable request to the authors.

## Author contributions

**Sadra Salehi-Mazandarani:** Conceptualization, Methodology, Investigation, Writing - original draft. **Sharareh Mahmoudian-Hamedani:** Methodology, Investigation, Writing - original draft. **Ziba Farajzadegan:** Writing - review and editing, Supervision, Validation. **Parvaneh Nikpour:** Funding acquisition, Supervision, Project administration, Writing - review and editing, Validation.

## Funding Sources

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

*   Received April 22, 2024.
*   Revision received April 22, 2024.
*   Accepted April 22, 2024.


*   © 2024, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## References

1.  1.Tan J-z, Yan Y, Wang X-x, Jiang Y, Xu HE. EZH2: biology, disease, and structure-based drug discovery. Acta Pharmacologica Sinica. 2014;35(2):161–74.
    
    

2.  2.He A, Shen X, Ma Q, Cao J, von Gise A, Zhou P, et al. PRC2 directly methylates GATA4 and represses its transcriptional activity. Genes & development. 2012;26(1):37–42.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiZ2VuZXNkZXYiO3M6NToicmVzaWQiO3M6NzoiMjYvMS8zNyI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDI0LzA0LzIyLzIwMjQuMDQuMjIuMjQzMDYxODEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

3.  3.Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer cell. 2013;23(6):839–52.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ccr.2013.04.008&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23684459&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F04%2F22%2F2024.04.22.24306181.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000320350900015&link_type=ISI) 

4.  4.Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. Journal of hematology & oncology. 2020;13(1):104.
    
    

5.  5.Huang J, Gou H, Yao J, Yi K, Jin Z, Matsuoka M, et al. The noncanonical role of EZH2 in cancer. Cancer science. 2021;112(4):1376–82.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/cas.14840&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33615636&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F04%2F22%2F2024.04.22.24306181.atom) 

6.  6.Li Z, Li M, Wang D, Hou P, Chen X, Chu S, et al. Post-translational modifications of EZH2 in cancer. Cell & bioscience. 2020;10(1):143.
    
    

7.  7.Yan KS, Lin CY, Liao TW, Peng CM, Lee SC, Liu YJ, et al. EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe? International journal of molecular sciences. 2017;18(6).
    
    

8.  8.Alajez NM, Shi W, Hui AB, Bruce J, Lenarduzzi M, Ito E, et al. Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell death & disease. 2010;1(10):e85.
    
    

9.  9.Wang J, Yang X, Li R, Zhang R, Hu D, Zhang Y, et al. LncRNA SNHG6 Inhibits Apoptosis by Regulating EZH2 Expression via the Sponging of MiR-101-3p in Esophageal Squamous-Cell Carcinoma. OncoTargets and therapy. 2020;13:11411–20.
    
    

10. 10.Huang HG, Tang XL, Huang XS, Zhou L, Hao YG, Zheng YF. Long noncoding RNA LINC00511 promoted cell proliferation and invasion via regulating miR-124-3p/EZH2 pathway in gastric cancer. European review for medical and pharmacological sciences. 2020;24(8):4232–45.
    
    

11. 11.Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146(3):353–8.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.cell.2011.07.014&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21802130&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F04%2F22%2F2024.04.22.24306181.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000293570500010&link_type=ISI) 

12. 12.Ma X, Lv L, Xing C. Circ_ 0115744 acts as miR-144 sponge to promote and predict the metastasis of colorectal cancer. Aging. 2021;13(4):5892–905.
    
    

13. 13.Guo K, Qian K, Shi Y, Sun T, Wang Z. LncRNA-MIAT promotes thyroid cancer progression and function as ceRNA to target EZH2 by sponging miR-150-5p. Cell death & disease. 2021;12(12):1097.
    
    

14. 14.Zheng Y, Li P, Ma J, Yang C, Dai S, Zhao C. Cancer-derived exosomal circ_0038138 enhances glycolysis, growth, and metastasis of gastric adenocarcinoma via the miR-198/EZH2 axis. Translational oncology. 2022;25:101479.
    
    

15. 15.Donyavi MH, Salehi-Mazandarani S, Nikpour P. Comprehensive competitive endogenous RNA network analysis reveals EZH2-related axes and prognostic biomarkers in hepatocellular carcinoma. Iranian journal of basic medical sciences. 2022;25(3):286–94.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.22038/IJBMS.2022.61570.13623&link_type=DOI) 

16. 16.Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE1OiIzNzIvbWFyMjlfMi9uNzEiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyNC8wNC8yMi8yMDI0LjA0LjIyLjI0MzA2MTgxLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

17. 17.Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research. 2003;13(11):2498–504.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NjoiZ2Vub21lIjtzOjU6InJlc2lkIjtzOjEwOiIxMy8xMS8yNDk4IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjQvMDQvMjIvMjAyNC4wNC4yMi4yNDMwNjE4MS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

18. 18.Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. eLife. 2015;4.
    
    

19. 19.Dudekula DB, Panda AC, Grammatikakis I, De S, Abdelmohsen K, Gorospe M. CircInteractome: A web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA biology. 2016;13(1):34–42.
    
    

20. 20.Liu Y, Li L, Song X. Exosomal circPVT1 derived from lung cancer promotes the progression of lung cancer by targeting miR-124-3p/EZH2 axis and regulating macrophage polarization. Cell cycle (Georgetown, Tex). 2022;21(5):514–30.
    
    

21. 21.Yang X, Wang L, Li R, Zhao Y, Gu Y, Liu S, et al. The long non-coding RNA PCSEAT exhibits an oncogenic property in prostate cancer and functions as a competing endogenous RNA that associates with EZH2. Biochem Biophys Res Commun. 2018;502(2):262–8.
    
    

22. 22.Wang J, Chen Y, Wang Q, Xu H, Jiang Q, Wang M, et al. LncRNA SPRY4-IT1 facilitates cell proliferation and angiogenesis of glioma via the miR-101-3p/EZH2/VEGFA signaling axis. Cancer medicine. 2023;12(6):7309–26.
    
    

23. 23.Liu D, Li Y, Luo G, Xiao X, Tao D, Wu X, et al. LncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells through up-regulating EZH2. Cancer letters. 2017;388:281–91.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.canlet.2016.12.005&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27998761&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F04%2F22%2F2024.04.22.24306181.atom) 

24. 24.Xu Y, Yao Y, Jiang X, Zhong X, Wang Z, Li C, et al. SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma. Journal of Experimental & Clinical Cancer Research. 2018;37(1):81.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s13046-018-0747-x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=29642935&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F04%2F22%2F2024.04.22.24306181.atom) 

25. 25.Chen D-l, Ju H-q, Lu Y-x, Chen L-z, Zeng Z-l, Zhang D-s, et al. Long non-coding RNA XIST regulates gastric cancer progression by acting as a molecular sponge of miR-101 to modulate EZH2 expression. Journal of Experimental & Clinical Cancer Research. 2016;35(1):142.
    
    

26. 26.Wu X, Dinglin X, Wang X, Luo W, Shen Q, Li Y, et al. Long noncoding RNA XIST promotes malignancies of esophageal squamous cell carcinoma via regulation of miR-101/EZH2. Oncotarget. 2017;8(44):76015–28.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.18632/oncotarget.18638&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=29100288&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F04%2F22%2F2024.04.22.24306181.atom) 

27. 27.Cao C, Xu Y, Du K, Mi C, Yang C, Xiang L, et al. LINC01303 functions as a competing endogenous RNA to regulate EZH2 expression by sponging miR-101-3p in gastric cancer. Journal of cellular and molecular medicine. 2019;23(11):7342–8.
    
    

28. 28.Zhang Y, Tang B, Song J, Yu S, Li Y, Su H, et al. Lnc-PDZD7 contributes to stemness properties and chemosensitivity in hepatocellular carcinoma through EZH2-mediated ATOH8 transcriptional repression. Journal of Experimental & Clinical Cancer Research. 2019;38(1):92.
    
    

29. 29.Xiao L, Wang W, Zhao J, Xu H, Li S, Yang X. lncRNA MALAT1 promotes cell proliferation and invasion by regulating the miR-101/EZH2 axis in oral squamous cell carcinoma. Oncology letters. 2020;20(5):164.
    
    

30. 30.Qiu BQ, Lin XH, Ye XD, Huang W, Pei X, Xiong D, et al. Long non-coding RNA PSMA3-AS1 promotes malignant phenotypes of esophageal cancer by modulating the miR-101/EZH2 axis as a ceRNA. Aging. 2020;12(2):1843–56.
    
    

31. 31.Wu K, Jiang Y, Zhou W, Zhang B, Li Y, Xie F, et al. Long Noncoding RNA RC3H2 Facilitates Cell Proliferation and Invasion by Targeting MicroRNA-101-3p/EZH2 Axis in OSCC. Molecular therapy Nucleic acids. 2020;20:97–110.
    
    

32. 32.Konno Y, Dong P, Xiong Y, Suzuki F, Lu J, Cai M, et al. MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget. 2014;5(15):6049–62.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.18632/oncotarget.2157&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25153722&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F04%2F22%2F2024.04.22.24306181.atom) 

33. 33.Yao Y, Liu Y, Jin F, Meng Z. LINC00662 Promotes Oral Squamous Cell Carcinoma Cell Growth and Metastasis through miR-144-3p/EZH2 Axis. Yonsei medical journal. 2021;62(7):640–9.
    
    

34. 34.Wang W, Ge L, Xu XJ, Yang T, Yuan Y, Ma XL, et al. LncRNA NEAT1 promotes endometrial cancer cell proliferation, migration and invasion by regulating the miR-144-3p/EZH2 axis. Radiology and oncology. 2019;53(4):434–42.
    
    

35. 35.Shi L, Hong X, Ba L, He X, Xiong Y, Ding Q, et al. Long non-coding RNA ZNFX1-AS1 promotes the tumor progression and metastasis of colorectal cancer by acting as a competing endogenous RNA of miR-144 to regulate EZH2 expression. Cell death & disease. 2019;10(3):150.
    
    

36. 36.Qu D, Yan B, Xin R, Ma T. A novel circular RNA hsa\_circ\_0020123 exerts oncogenic properties through suppression of miR-144 in non-small cell lung cancer. American journal of cancer research. 2018;8(8):1387–402.
    
    

37. 37.Cao J, Han X, Qi X, Jin X, Li X. TUG1 promotes osteosarcoma tumorigenesis by upregulating EZH2 expression via miR-144-3p. International journal of oncology. 2017;51(4):1115–23.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3892/ijo.2017.4110&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=28902349&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F04%2F22%2F2024.04.22.24306181.atom) 

38. 38.Yan H, Han L, He N, Li R, He S. Upregulated Circular RNA KIF4A Promotes Cell Migration and Invasion by Regulating MicroRNA-144-3p/EZH2 Axis in Gastric Cancer. Journal of oncology. 2022;2022:3985621.
    
    

39. 39.Sha J, Xia L, Han Q, Chi C, Zhu Y, Pan J, et al. Downregulation of circ-TRPS1 suppressed prostatic cancer prognoses by regulating miR-124-3p/EZH2 axis-mediated stemness. American journal of cancer research. 2020;10(12):4372–85.
    
    

40. 40.Yang X, Wang J, Li H, Sun Y, Tong X. Downregulation of hsa\_circ\_0026123 suppresses ovarian cancer cell metastasis and proliferation through the miRl11124l113p/EZH2 signaling pathway. International journal of molecular medicine. 2021;47(2):668–76.
    
    

41. 41.Xiao D, Cui X, Wang X. Long noncoding RNA XIST increases the aggressiveness of laryngeal squamous cell carcinoma by regulating miR-124-3p/EZH2. Experimental cell research. 2019;381(2):172–8.
    
    

42. 42.Zhang Y, Wang X, Wang P, Zhang X, Han SH, Huo F. LncRNA DS Cell Adhesion Molecule Antisense RNA 1 Facilitates Oral Squamous Cell Carcinoma Progression through The microRNA-138-5p/ Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit Axis. Cell journal. 2022;24(5):222–9.
    
    

43. 43.Zou S, Gao Y, Zhang S. lncRNA HCP5 acts as a ceRNA to regulate EZH2 by sponging miRl11138l115p in cutaneous squamous cell carcinoma. International journal of oncology. 2021;59(2).
    
    

44. 44.Deng Y, Cheng L, Lv Z, Zhu H, Meng X. lncRNA SNHG7 promotes cell proliferation in glioma by acting as a competing endogenous RNA and sponging miR-138-5p to regulate EZH2 expression. Oncology letters. 2021;22(1):565.
    
    

45. 45.Hong Y, He H, Sui W, Zhang J, Zhang S, Yang D. Long non-coding RNA H1 promotes cell proliferation and invasion by acting as a ceRNA of miRl11138 and releasing EZH2 in oral squamous cell carcinoma. International journal of oncology. 2018;52(3):901–12.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F04%2F22%2F2024.04.22.24306181.atom) 

46. 46.Shi Y, Yang X, Xue X, Sun D, Cai P, Song Q, et al. HANR promotes hepatocellular carcinoma progression via miR-214/EZH2/TGF-β axis. Biochemical and Biophysical Research Communications. 2018;506(1):189–93.
    
    

47. 47.Xu M, Chen X, Lin K, Zeng K, Liu X, Xu X, et al. lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer. Journal of hematology & oncology. 2019;12(1):3.
    
    

48. 48.Xu C, He T, Li Z, Liu H, Ding B. Regulation of HOXA11-AS/miR-214-3p/EZH2 axis on the growth, migration and invasion of glioma cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2017;95:1504–13.
    
    

49. 49.Lin T, Dai Y, Guo X, Chen W, Zhao J, Cao L, et al. Silencing Of hsa\_circ\_0008450 Represses Hepatocellular Carcinoma Progression Through Regulation Of microRNA-214-3p/EZH2 Axis. Cancer management and research. 2019;11:9133–43.
    
    

50. 50.Zhang M, Duan W, Sun W. LncRNA SNHG6 promotes the migration, invasion, and epithelial-mesenchymal transition of colorectal cancer cells by miR-26a/EZH2 axis. OncoTargets and therapy. 2019;12:3349–60.
    
    

51. 51.Kong WQ, Liang JJ, Du J, Ye ZX, Gao P, Liang YL. Long Noncoding RNA DLX6-AS1 Regulates the Growth and Aggressiveness of Colorectal Cancer Cells Via Mediating the miR-26a/EZH2 Axis. Cancer biotherapy & radiopharmaceuticals. 2021;36(9):753–64.
    
    

52. 52.Wang SH, Yang Y, Wu XC, Zhang MD, Weng MZ, Zhou D, et al. Long non-coding RNA MINCR promotes gallbladder cancer progression through stimulating EZH2 expression. Cancer letters. 2016;380(1):122–33.
    
    

53. 53.Sun M, Nie F, Wang Y, Zhang Z, Hou J, He D, et al. LncRNA HOXA11-AS Promotes Proliferation and Invasion of Gastric Cancer by Scaffolding the Chromatin Modification Factors PRC2, LSD1, and DNMT1. Cancer research. 2016;76(21):6299–310.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NjoiY2FucmVzIjtzOjU6InJlc2lkIjtzOjEwOiI3Ni8yMS82Mjk5IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjQvMDQvMjIvMjAyNC4wNC4yMi4yNDMwNjE4MS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

54. 54.Liu L, Li X, Shi Y, Chen H. Long noncoding RNA DLGAP1-AS1 promotes the progression of glioma by regulating the miR-1297/EZH2 axis. Aging. 2021;13(8):12129–42.
    
    

55. 55.Min J, Ma J, Wang Q, Yu D. Long non-coding RNA SNHG1 promotes bladder cancer progression by upregulating EZH2 and repressing KLF2 transcription. Clinics (Sao Paulo, Brazil). 2022;77:100081.
    
    

56. 56.Liu X, Cui L, Hua D. Long Noncoding RNA XIST Regulates miR-137-EZH2 Axis to Promote Tumor Metastasis in Colorectal Cancer. Oncology research. 2018;27(1):99–106.
    
    

57. 57.Wang S, Tong H, Su T, Zhou D, Shi W, Tang Z, et al. CircTP63 promotes cell proliferation and invasion by regulating EZH2 via sponging miR-217 in gallbladder cancer. Cancer cell international. 2021;21(1):608.
    
    

58. 58.Li Y, Tian M, Zhang D, Zhuang Y, Li Z, Xie S, et al. Long Non-Coding RNA Myosin Light Chain Kinase Antisense 1 Plays an Oncogenic Role in Gallbladder Carcinoma by Promoting Chemoresistance and Proliferation. Cancer management and research. 2021;13:6219–30.
    
    

59. 59.Wang Y, Li Y, He H, Wang F. Circular RNA circ-PRMT5 facilitates non-small cell lung cancer proliferation through upregulating EZH2 via sponging miR-377/382/498. Gene. 2019;720:144099.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.gene.2019.144099&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F04%2F22%2F2024.04.22.24306181.atom) 

60. 60.Zhao L, Sun H, Kong H, Chen Z, Chen B, Zhou M. The Lncrna-TUG1/EZH2 Axis Promotes Pancreatic Cancer Cell Proliferation, Migration and EMT Phenotype Formation Through Sponging Mir-382. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2017;42(6):2145–58.
    
    

61. 61.Yong W, Zhuoqi X, Baocheng W, Dongsheng Z, Chuan Z, Yueming S. Hsa\_circ\_0071589 promotes carcinogenesis via the miR-600/EZH2 axis in colorectal cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2018;102:1188–94.
    
    

62. 62.Li Y, Wan Q, Wang W, Mai L, Sha L, Mashrah M, et al. LncRNA ADAMTS9-AS2 promotes tongue squamous cell carcinoma proliferation, migration and EMT via the miR-600/EZH2 axis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2019;112:108719.
    
    

63. 63.Zheng M, Jiang YP, Chen W, Li KD, Liu X, Gao SY, et al. Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma. Oncotarget. 2015;6(9):6797–810.
    
    

64. 64.Xie JJ, Li WH, Li X, Ye W, Shao CF. LncRNA MALAT1 promotes colorectal cancer development by sponging miR-363-3p to regulate EZH2 expression. Journal of biological regulators and homeostatic agents. 2019;33(2):331–43.
    
    

65. 65.Chen Z, Yang P, Li W, He F, Wei J, Zhang T, et al. Expression of EZH2 is associated with poor outcome in colorectal cancer. Oncology letters. 2018;15(3):2953–61.
    
    

66. 66.Vilorio-Marqués L, Martín V, Diez-Tascón C, González-Sevilla MF, Fernández-Villa T, Honrado E, et al. The role of EZH2 in overall survival of colorectal cancer: a meta-analysis. Scientific Reports. 2017;7(1):13806.
    
    

67. 67.Chen JF, Luo X, Xiang LS, Li HT, Zha L, Li N, et al. EZH2 promotes colorectal cancer stem-like cell expansion by activating p21cip1-Wnt/β-catenin signaling. Oncotarget. 2016;7(27):41540–58.
    
    

68. 68.Xu J, Wang Z, Lu W, Jiang H, Lu J, Qiu J, et al. EZH2 promotes gastric cancer cells proliferation by repressing p21 expression. Pathology, research and practice. 2019;215(6):152374.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.prp.2019.03.003&link_type=DOI) 

69. 69.Lee SW, Park DY, Kim MY, Kang C. Synergistic triad epistasis of epigenetic H3K27me modifier genes, EZH2, KDM6A, and KDM6B, in gastric cancer susceptibility. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2019;22(3):640–4.
    
    

70. 70.Zhou Y, Du WD, Wu Q, Liu Y, Chen G, Ruan J, et al. EZH2 genetic variants affect risk of gastric cancer in the Chinese Han population. Molecular carcinogenesis. 2014;53(8):589–97.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/mc.21871&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22228224&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F04%2F22%2F2024.04.22.24306181.atom) 

71. 71.Fujii S, Ochiai A. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer science. 2008;99(4):738–46.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/j.1349-7006.2008.00743.x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18377425&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F04%2F22%2F2024.04.22.24306181.atom) 

72. 72.Jie B, Weilong C, Ming C, Fei X, Xinghua L, Junhua C, et al. Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus. The international journal of biochemistry & cell biology. 2015;65:104–12.
    
    

73. 73.Yu W, Liu N, Song X, Chen L, Wang M, Xiao G, et al. EZH2: An Accomplice of Gastric Cancer. Cancers. 2023;15(2).
    
    

74. 74.Zhao L, Yu Y, Wu J, Bai J, Zhao Y, Li C, et al. Role of EZH2 in oral squamous cell carcinoma carcinogenesis. Gene. 2014;537(2):197–202.
    
    

75. 75.Kidani K, Osaki M, Tamura T, Yamaga K, Shomori K, Ryoke K, et al. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral oncology. 2009;45(1):39–46.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.oraloncology.2008.03.016&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18619895&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F04%2F22%2F2024.04.22.24306181.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000262607900007&link_type=ISI) 

76. 76.Parlatescu I, Gheorghe C, Coculescu E, Tovaru S. Oral leukoplakia - an update. Maedica. 2014;9(1):88–93.
    
    

77. 77.Ganesh D, Dafar A, Niklasson J, Sandberg I, Braz-Silva P, Sapkota D, et al. EZH2 Expression Correlates With T-Cell Infiltration in Oral Leukoplakia and Predicts Cancer Transformation. Anticancer research. 2023;43(4):1533–42.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTA6ImFudGljYW5yZXMiO3M6NToicmVzaWQiO3M6OToiNDMvNC8xNTMzIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjQvMDQvMjIvMjAyNC4wNC4yMi4yNDMwNjE4MS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

78. 78.Fan K, Zhang CL, Qi YF, Dai X, Birling Y, Tan ZF, et al. Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis. BioMed research international. 2020;2020:2380124.
    
    

79. 79.Gallardo A, Molina A, Asenjo HG, Lopez-Onieva L, Martorell-Marugán J, Espinosa-Martinez M, et al. EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumour colonization. Oncogene. 2022;41(28):3611–24.
    
    

80. 80.Entezari M, Taheriazam A, Paskeh MDA, Sabouni E, Zandieh MA, Aboutalebi M, et al. The pharmacological and biological importance of EZH2 signaling in lung cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023;160:114313.
    
    

81. 81.Mao M, Zhang J, Xiang Y, Gong M, Deng Y, Ye D. Role of exosomal competitive endogenous RNA (ceRNA) in diagnosis and treatment of malignant tumors. Bioengineered. 2022;13(5):12156–68.
    
    

82. 82.Zhang X, He X, Liu Y, Zhang H, Chen H, Guo S, et al. MiR-101-3p inhibits the growth and metastasis of non-small cell lung cancer through blocking PI3K/AKT signal pathway by targeting MALAT-1. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2017;93:1065–73.
    
    

83. 83.Wu F, Huang W, Yang L, Xu F. MicroRNA-101-3p regulates gastric cancer cell proliferation, invasion and apoptosis by targeting PIM 1 expression. Cellular and molecular biology (Noisy-le-Grand, France). 2019;65(7):118–22.
    
    

84. 84.Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity. 2013;39(3):611–21.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.immuni.2013.08.025&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24012420&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F04%2F22%2F2024.04.22.24306181.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000330949600022&link_type=ISI) 

85. 85.Liu N, Yang C, Gao A, Sun M, Lv D. MiR-101: An Important Regulator of Gene Expression and Tumor Ecosystem. Cancers. 2022;14(23).
    
    

86. 86.Kooshkaki O, Rezaei Z, Rahmati M, Vahedi P, Derakhshani A, Brunetti O, et al. MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers. International journal of molecular sciences. 2020;21(7).
    
    

87. 87.Jia X, Wang X, Guo X, Ji J, Lou G, Zhao J, et al. MicroRNA-124: An emerging therapeutic target in cancer. Cancer medicine. 2019;8(12):5638–50.
    
    

88. 88.Yeh M, Oh CS, Yoo JY, Kaur B, Lee TJ. Pivotal role of microRNA-138 in human cancers. American journal of cancer research. 2019;9(6):1118–26.
    
    

89. 89.Sharma T, Hamilton R, Mandal CC. miR-214: a potential biomarker and therapeutic for different cancers. Future oncology (London, England). 2015;11(2):349–63.
    
    

90. 90.Tombolan L, Millino C, Pacchioni B, Cattelan M, Zin A, Bonvini P, et al. Circulating miR-26a as Potential Prognostic Biomarkers in Pediatric Rhabdomyosarcoma. Frontiers in Genetics. 2020;11.
    
    

91. 91.Liu T, Wang Z, Dong M, Wei J, Pan Y. MicroRNA-26a inhibits cell proliferation and invasion by targeting FAM98A in breast cancer. Oncology letters. 2021;21(5):367.
    
    

92. 92.Alizadeh-Fanalou S, Khosravi M, Alian F, Rokhsartalb-Azar S, Nazarizadeh A, Karimi-Dehkordi M, et al. Dual role of microRNA-1297 in the suppression and progression of human malignancies. Biomedicine & Pharmacotherapy. 2021;141:111863.
    
    

93. 93.Zhou S, Zhu C, Pang Q, Liu HC. MicroRNA-217: A regulator of human cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2021;133:110943.
    
    

94. 94.Wang Y, Chen R, Zhou X, Guo R, Yin J, Li Y, et al. miR-137: A Novel Therapeutic Target for Human Glioma. Molecular therapy Nucleic acids. 2020;21:614–22.
    
    

95. 95.Shan L, Song P, Zhao Y, An N, Xia Y, Qi Y, et al. miR-600 promotes ovarian cancer cells stemness, proliferation and metastasis via targeting KLF9. Journal of ovarian research. 2022;15(1):52.
    
    

96. 96.Zhou H, Gan M, Jin X, Dai M, Wang Y, Lei Y, et al. miRl11382 inhibits breast cancer progression and metastasis by affecting the M2 polarization of tumorl11associated macrophages by targeting PGCl111α Corrigendum in /10.3892/ijo.2022.5449. International journal of oncology. 2022;61(4):126.
    
    

97. 97.Sang W, Zhu R, Liu D, Gong M. LncRNA SPRY4l11IT1 is upregulated and promotes the proliferation of prostate cancer cells under hypoxia in vitro. Oncology letters. 2023;25(4):138.
    
    

98. 98.Zhang Y, Chen H, Yuan R, Wang Y, Zhang D, Zeng Q, et al. PDK1-stabilized LncRNA SPRY4-IT1 promotes breast cancer progression via activating NF-κB signaling pathway. Molecular carcinogenesis. 2023;62(7):1009–24.
    
    

99. 99.Yang J, Qi M, Fei X, Wang X, Wang K. Long non-coding RNA XIST: a novel oncogene in multiple cancers. Molecular Medicine. 2021;27(1):159.
    
    

100.100.Ghafouri-Fard S, Dashti S, Farsi M, Taheri M, Mousavinejad SA. X-Inactive-Specific Transcript: Review of Its Functions in the Carcinogenesis. Frontiers in Cell and Developmental Biology. 2021;9.
    
    

101.101.Zhang S, Qiu D, Xie X, Shen Y. Clinicopathological and prognostic value of SNHG6 in cancers: a systematic review and a meta-analysis. BMC Cancer. 2020;20(1):343.
    
    

102.102.Wei C, Zhao L, Liang H, Zhen Y, Han L. Recent advances in unraveling the molecular mechanisms and functions of HOXA11l11AS in human cancers and other diseases (Review). Oncology reports. 2020;43(6):1737–54.
    
    

103.103.Amodio N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P, et al. MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. Journal of hematology & oncology. 2018;11(1):63.
    
    

104.104.Hou J, Zhang G, Wang X, Wang Y, Wang K. Functions and mechanisms of lncRNA MALAT1 in cancer chemotherapy resistance. Biomarker Research. 2023;11(1):23.
    
    

105.105.Zhou H, Sun L, Wan F. Molecular mechanisms of TUG1 in the proliferation, apoptosis, migration and invasion of cancer cells. Oncology letters. 2019;18(5):4393–402.
    
    

106.106.Xu J, Lin Q, Zhao X. Circular RNA 0000311 Aggravates the Aggressiveness of Oral Squamous Cell Carcinoma via miR-876-5p/EZH2 Axis. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer. 2023;42(3):43–52.
    
    

107.107.Pan T, Xue M. LncRNA-NNT-AS1 contributes to the progression of glioma by miR-582-5p/EZH2 axis. Cytotechnology. 2021;73(3):473–82.
    
    

108.108.Yuan DH, Zhao J, Shao GF. Circular RNA TTBK2 promotes the development of human glioma cells via miR-520b/EZH2 axis. European review for medical and pharmacological sciences. 2019;23(24):10886–98.
    
    

109.109.Qiu C, Li S, Sun D, Yang S. lncRNA PVT1 accelerates progression of non-small cell lung cancer via targeting miRNA-526b/EZH2 regulatory loop. Oncology letters. 2020;19(2):1267–72.
    
    

110.110.Lei D, Wang T. circSYPL1 Promotes the Proliferation and Metastasis of Hepatocellular Carcinoma via the Upregulation of EZH2 Expression by Competing with hsa-miR-506-3p. Journal of oncology. 2022;2022:2659563.
    
    

111.111.Dong Q, Qiu H, Piao C, Li Z, Cui X. LncRNA SNHG4 promotes prostate cancer cell survival and resistance to enzalutamide through a let-7a/RREB1 positive feedback loop and a ceRNA network. Journal of experimental & clinical cancer research : CR. 2023;42(1):209.
    
    

112.112.Chen Y, Gu M, Liu C, Wan X, Shi Q, Chen Q, et al. Long noncoding RNA FOXC2-AS1 facilitates the proliferation and progression of prostate cancer via targeting miR-1253/EZH2. Gene. 2019;686:37–42.
    
    

113.113.Xie Y, Zhang H, Guo X-J, Feng Y-C, He R-Z, Li X, et al. Let-7c inhibits cholangiocarcinoma growth but promotes tumor cell invasion and growth at extrahepatic sites. Cell death & disease. 2018;9(2):249.
    
    

114.114.Ma X, Li Y, Song Y, Xu G. Long Noncoding RNA CCDC26 Promotes Thyroid Cancer Malignant Progression via miR-422a/EZH2/Sirt6 Axis. OncoTargets and therapy. 2021;14:3083–94.
    
    

115.115.Lin Y, Wu T, Yang M, Duangmano S, Chaiwongsa R, Pornprasert S, et al. Upregulation of long noncoding RNA FERRE promoted growth and invasion of breast cancer through modulating miR-19a-5p/EZH2 axis. European review for medical and pharmacological sciences. 2020;24(21):11154–64.